PMN ProMIS Neurosciences Inc.: Bathi saben saham sajroning taun lumaku

Anticipation of the results from Alzheimer's disease antibody trials serves as the primary trigger for ProMIS Neurosciences (PMN), while the market valuation already prices in the liquidity shortage. The EPS growth rate over the last 12 months YoY demonstrates profit dynamics, with the latest value recorded as -169.30. Patents for selective therapy establish a foundation for future royalties, although a high cash burn rate and fierce competition create risks of financial instability.

Developing selective antibodies in partnership with medical institutes requires colossal investments, which directly impacts the net earnings per share of ProMIS Neurosciences (PMN). By analyzing the year-over-year EPS dynamics (trailing 12 months), an investor assesses the annual growth of this metric over a rolling year to determine the business's ability to scale capitalization and maintain cash flow amid market volatility.